PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST DISSEMINATED CANDIDIASIS AND OTHER INFECTIOUS AGENTS
    3.
    发明申请
    PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST DISSEMINATED CANDIDIASIS AND OTHER INFECTIOUS AGENTS 审中-公开
    药物组合物和抗肿瘤药物和其他感染性药物的方法

    公开(公告)号:US20140037689A1

    公开(公告)日:2014-02-06

    申请号:US13785835

    申请日:2013-03-05

    IPC分类号: A61K39/00

    摘要: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue. The Als protein family member can be derived from a Candida strain selected from the group consisting of Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata and Candida parapsilosis and the Als protein family member includes Als1p, Als3p, Als5p, Als6p, Als7p or Als9p. Also provided is a method of treating or preventing Staphylococcus aureus infections.

    摘要翻译: 本发明提供了包含具有细胞粘附活性的分离的Als蛋白家族成员或其免疫原性片段的疫苗,其在药学上可接受的培养基中与佐剂一起使用。 本发明还提供了治疗或预防血液弥漫性或粘膜皮肤念珠菌病的方法。 还提供了治疗或预防弥漫性念珠菌病的方法,其包括施用有效量的具有细胞粘附活性的分离的Als蛋白家族成员或其功能片段,以抑制念珠菌与宿主细胞或组织的结合或侵入。 Als蛋白家族成员可以衍生自选自白色念珠菌,克罗斯假丝酵母,热带假丝酵母,光滑假丝酵母和副假丝酵母的念珠菌菌株,Als蛋白家族成员包括Als1p,Als3p,Als5p,Als6p,Als7p或Als9p 。 还提供了治疗或预防金黄色葡萄球菌感染的方法。

    Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
    4.
    发明授权
    Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases 有权
    疫苗组合物和治疗毛霉菌病及其他真菌病的方法

    公开(公告)号:US08444985B2

    公开(公告)日:2013-05-21

    申请号:US12661609

    申请日:2010-03-19

    摘要: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary to at least 18 contiguous nucleotides of FTR sequence; an antisense; a small interfering RNA or an antibody inhibitor of FTR. The vaccine compositions of the invention can further include an adjuvant.

    摘要翻译: 本发明提供治疗和预防真菌病或包括毛霉菌病的病症的治疗组合物和方法。 本发明的治疗方法和组合物包括具有多肽的FTR多肽或抗原性片段的疫苗组合物; 包含与FTR序列的至少18个连续核苷酸基本互补的核苷酸序列的载体; 反义词 小干扰RNA或FTR的抗体抑制剂。 本发明的疫苗组合物还可包含佐剂。

    PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST DISSEMINATED CANDIDIASIS AND OTHER INFECTIOUS AGENTS
    5.
    发明申请
    PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST DISSEMINATED CANDIDIASIS AND OTHER INFECTIOUS AGENTS 审中-公开
    药物组合物和抗肿瘤药物和其他感染性药物的方法

    公开(公告)号:US20120014995A1

    公开(公告)日:2012-01-19

    申请号:US12987949

    申请日:2011-01-10

    IPC分类号: A61K39/00 A61P37/06 A61P31/10

    摘要: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue. The Als protein family member can be derived from a Candida strain selected from the group consisting of Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata and Candida parapsilosis and the Als protein family member includes Als1p, Als3p, Als5p, Als6p, Als7p or Als9p. Also provided is a method of treating or preventing Staphylococcus aureus infections. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.

    摘要翻译: 本发明提供了包含具有细胞粘附活性的分离的Als蛋白家族成员或其免疫原性片段的疫苗,其在药学上可接受的培养基中与佐剂一起使用。 本发明还提供了治疗或预防血液弥漫性或粘膜皮肤念珠菌病的方法。 该方法包括在药学上可接受的培养基中施用免疫原性量的具有细胞粘附活性的分离的Als蛋白家族成员或其免疫原性片段的疫苗。 还提供了治疗或预防弥漫性念珠菌病的方法,其包括施用有效量的具有细胞粘附活性的分离的Als蛋白家族成员或其功能片段,以抑制念珠菌与宿主细胞或组织的结合或侵入。 Als蛋白家族成员可以衍生自选自白色念珠菌,克罗斯假丝酵母,热带假丝酵母,光滑假丝酵母和副假丝酵母的念珠菌菌株,Als蛋白家族成员包括Als1p,Als3p,Als5p,Als6p,Als7p或Als9p 。 还提供了治疗或预防金黄色葡萄球菌感染的方法。 该方法包括在药学上可接受的培养基中施用免疫原性量的具有细胞粘附活性的分离的Als蛋白家族成员或其免疫原性片段的疫苗。

    Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
    6.
    发明授权
    Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis 失效
    用于接种传播性念珠菌病的药物组合物和方法

    公开(公告)号:US07067138B1

    公开(公告)日:2006-06-27

    申请号:US09715876

    申请日:2000-11-18

    摘要: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface protein, Als1p, is a downstream effector of the filamentation regulatory pathway and is regulated by Efg1p. Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene product from the ALS1 gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

    摘要翻译: 白色念珠菌血液感染在住院患者中引起显着的发病率和死亡率。 丝状体形成和粘附宿主细胞是白色念珠菌的关键毒力因子。 已经发现多个丝状调节途径,但是这些调节途径的下游作用因素仍然未知。 细胞表面蛋白Als1p是丝状细胞调节通路的下游效应物,受Efg1p调控。 Als1p在体外介导对内皮细胞的依从性,是毒力所必需的。 使用本文公开的组合物和方法描述了由有机体粘附的阻断。 特别地,作为疫苗施用由ALS1基因家族的基因产物组成的药物组合物,以产生能够阻断生物的粘附的免疫应答。